Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers
نویسندگان
چکیده
منابع مشابه
Mesothelin-targeted agents in clinical trials and in preclinical development.
Mesothelin is a tumor differentiation antigen that is highly expressed in several malignant diseases in humans, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. The limited expression of mesothelin on normal human tissues and its high expression in many common cancers make it an attractive candidate for cancer therapy. Several agents, including an immunotoxin,...
متن کاملMesothelin-targeted immunotherapies for malignant pleural mesothelioma.
Despite the use of aggressive trimodality therapy consisting of neoadjuvant chemotherapy, surgery, and hemithoracic radiation, the median survival of patients with malignant pleural mesothelioma (MPM) is 12 to 18 months (1,2). Immune responses have been shown to be beneficial in MPM patients (3,4); therefore, focusing immunotherapeutic strategies on promoting these immune responses is an attrac...
متن کاملTargeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma
The cell surface receptor CD70 has been previously reported as a promising target for B-cell lymphomas and several solid cancers including renal cell carcinoma. We describe herein the characterization and efficacy of a novel CD70 targeted thorium-227 conjugate (CD70-TTC) comprising the combination of the three components, a CD70 targeting antibody, a chelator moiety and the short-range, high-en...
متن کاملMesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
Article history: Received 24 September 2017 Accepted 24 September 2017 Available online 25 September 2017 phatic invasion by increasing cell adhesion to lymphatic endothelial cells (Kawamata et al., 2014). Our group investigated mesothelin expression in gastrointestinal cancers using immunohistochemistry (IHC), especially focusing on the localization of mesothelin, i.e., “luminal membrane-posit...
متن کاملEfficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.
The RG7787 mesothelin-targeted recombinant immunotoxin (RIT) consists of an antibody fragment targeting mesothelin (MSLN) fused to a 24-kD fragment of Pseudomonas exotoxin A for cell killing. Compared with prior RITs, RG7787 has improved properties for clinical development including decreased nonspecific toxicity and immunogenicity and resistance to degradation by lysosomal proteases. MSLN is a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2019
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-18-3476